Welcome to our dedicated page for Adc Therapeutics Sa news (Ticker: ADCT), a resource for investors and traders seeking the latest updates and insights on Adc Therapeutics Sa stock.
ADC Therapeutics SA (ADCT) is a commercial-stage biopharmaceutical leader pioneering antibody drug conjugates (ADCs) for advanced oncology treatments. This page serves as the definitive source for all company announcements, including clinical trial updates, regulatory milestones, and strategic partnerships.
Investors and researchers will find curated press releases and news articles detailing ADCT's progress in developing targeted therapies for hematologic malignancies and solid tumors. Our collection includes updates on product commercialization, clinical study results, and research collaborations, providing critical insights into the company's scientific and operational trajectory.
Key content categories cover quarterly financial results, FDA/EMA regulatory filings, and advancements in ADC technology. Bookmark this page to stay informed about ADCT's innovations in precision oncology and its growing impact on cancer treatment paradigms.
ADC Therapeutics SA (NYSE: ADCT), a leader in antibody drug conjugates (ADCs), has granted options to purchase 17,900 common shares to four new employees on September 3, 2024. These grants, approved by the Compensation Committee, are part of the company's Inducement Plan to attract and retain top talent. The options will vest over four years, with 25% vesting on the first anniversary and 1/48th vesting monthly thereafter, contingent on continued employment. This move aligns with NYSE's Listed Company Manual Rule 303A.08, demonstrating ADC Therapeutics' commitment to incentivizing high performance and long-term success.
ADC Therapeutics SA (NYSE: ADCT), a leader in antibody drug conjugates, has announced its participation in two major investor conferences this September. The company will be represented by CEO Ameet Mallik at both events:
1. H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, featuring a virtual fireside chat at 7:00 a.m. ET.
2. 10th Cantor Global Healthcare Conference 2024 on September 18, 2024, with a fireside chat scheduled from 11:30-12:00 p.m. ET.
Live webcasts of both presentations will be accessible through the company's website, with replays available for approximately 30 days after each event.
ADC Therapeutics reported Q2 2024 financial results and operational updates. ZYNLONTA achieved commercial profitability in H1 2024, with net sales of $17.0 million in Q2. The LOTIS-7 trial is progressing, with efficacy and safety data expected by year-end 2024. LOTIS-5 trial enrollment is expected to complete before year-end 2024. The company's cash position of $300.1 million is expected to extend runway into mid-2026.
Financial highlights include:
- Net product revenues of $34.9 million for H1 2024
- R&D expense decreased to $50.0 million for H1 2024
- Net loss of $83.2 million, or $0.93 per share for H1 2024
- Adjusted net loss of $55.5 million, or $0.62 per share for H1 2024
ADC Therapeutics SA (NYSE: ADCT), a leader in antibody drug conjugates (ADCs), has granted options to purchase 38,600 common shares to three new employees on August 1, 2024. These grants, approved by the Compensation Committee, are part of the company's Inducement Plan to attract and retain top talent. The options will vest over four years, with 25% vesting on the first anniversary and 1/48th vesting monthly thereafter, contingent on continued employment. This action aligns with NYSE's Listed Company Manual Rule 303A.08 for employment inducement exemptions.
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader in antibody drug conjugates (ADCs), has announced a conference call and live webcast scheduled for August 6, 2024, at 8:30 a.m. EDT. The event will cover the company's second quarter 2024 financial results and provide operational updates. Interested parties can register for the call to receive dial-in details and a unique PIN. A live webcast will be available on the company's investor relations website, with an archived version accessible for 30 days after the event.
ADC Therapeutics SA (NYSE: ADCT) announced the issuance of stock options totaling 172,400 common shares to six new employees on July 1, 2024. These grants are part of an inducement plan to attract and retain talent, approved by the company's Board's Compensation Committee.
The grants are structured to vest 25% on the first anniversary of the grant date, with the remaining shares vesting monthly over the following three years, contingent on continued employment. This initiative is in compliance with NYSE Rule 303A.08.
ADC Therapeutics (NYSE: ADCT) will join the Russell 2000® and Russell 3000® indexes effective July 1, 2024. This inclusion follows the 2024 Russell US Indexes annual reconstitution, capturing the 4,000 largest US stocks as of April 30, 2024, based on market capitalization. CEO Ameet Mallik stated that this milestone validates ADC Therapeutics' corporate and capital allocation strategy, and highlights progress in their hematology and solid tumor portfolios. The Russell indexes, managed by FTSE Russell, are benchmarks for about $10.5 trillion in assets and guide investment strategies for many institutional investors. Membership in the Russell 3000® ensures automatic inclusion in either the Russell 1000® or Russell 2000® indexes.
ADC Therapeutics (NYSE: ADCT) has announced the issuance of stock options to three new employees as part of its Inducement Plan. A total of 109,800 options were granted on June 3, 2024, to motivate and reward the new hires. These grants were approved by the Compensation Committee of the Board of Directors and made under the NYSE's Rule 303A.08 exemption. The options vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly thereafter, contingent on continued employment.
ADC Therapeutics announced that CEO Ameet Mallik will present a company overview at the Jefferies Global Healthcare Conference on June 6, 2024, at 11:30 a.m. ET.
The presentation will be webcast live and available on the company's investor relations website, with a replay accessible for about 30 days.
ADC Therapeutics (NYSE: ADCT) announced that CEO Ameet Mallik will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ. The event is scheduled for Monday, May 20, 2024, at 2:00 p.m. ET. The presentation will be webcast live and available for replay for approximately 30 days on the company's investor website.
FAQ
What is the current stock price of Adc Therapeutics Sa (ADCT)?
What is the market cap of Adc Therapeutics Sa (ADCT)?
